A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to evaluate the safety and pharmacokinetics of
administering various dose regimens of ramucirumab in participants with advanced gastric
cancer whose disease has progressed during or following prior chemotherapy.